Out-Licensing in Pharmaceutical Research and Development
ISBN
978-3-527-33913-6
Type
book section
Date Issued
2016
Author(s)
Editor(s)
Abstract
Seventy percent of pharmaceutical companies expect their collaborations will primarily take the traditional forms of out-licensing products or technology. Whereas research alliances, in-licensing, and co-development are quite established and traditional collaboration approaches, many established pharmaceutical companies have long considered out-licensing a difficult task.
The purpose of this chapter is to illustrate how out-licensing by pharmaceutical companies can contribute to an increase in research and development (R&D) efficiency. A case study of Novartis demonstrates how the out-licensing can be successfully adopted and managed.
Successfully executed out-licensing programs provide pharmaceutical firms with several benefits such as additional revenue generation, cost- and resource effectiveness, and mitigation of R&D related risks.
The purpose of this chapter is to illustrate how out-licensing by pharmaceutical companies can contribute to an increase in research and development (R&D) efficiency. A case study of Novartis demonstrates how the out-licensing can be successfully adopted and managed.
Successfully executed out-licensing programs provide pharmaceutical firms with several benefits such as additional revenue generation, cost- and resource effectiveness, and mitigation of R&D related risks.
Language
English
Keywords
licensing
pharma
intellectual property
collaboration
alliances
out-licensing
Novartis
risk management
risk management
HSG Classification
contribution to practical use / society
HSG Profile Area
SoM - Business Innovation
Book title
Value Creation in the Pharmaceutical Industry : The Critical Path to Innovation
Publisher
Wiley-VCH
Publisher place
Weinheim
Start page
363
End page
380
Subject(s)
Division(s)
Eprints ID
248283